Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.68 |
| ▸ | RAB9A | P51151 | 5/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11641118 | 0.84 | NPC1 (0.69) | NPC1RAB9ACYP3A4CYP2C19CYP1A2 | |
| SCHEMBL28930128 | 0.84 | NPC1 (0.65) | NPC1RAB9ACYP3A4CYP2C19CYP1A2 | |
| SCHEMBL17084391 | 0.83 | NPC1 (0.72) | NPC1RAB9ACYP3A4CYP2C19CYP1A2 | |
| SCHEMBL26105174 | 0.81 | NPC1 (0.56) | NPC1RAB9ACYP3A4CYP2C19CYP1A2 | |
| SCHEMBL17084387 | 0.81 | NPC1 (1.00) | NPC1RAB9ACYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL17084385 | 0.81 | NPC1 (1.00) | NPC1RAB9ACYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL1181029 | 0.80 | NPC1 (0.87) | NPC1RAB9ACYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL11645867 | 0.80 | NPC1 (0.63) | NPC1RAB9ACYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL11645573 | 0.80 | NPC1 (0.63) | NPC1RAB9ACYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL11457996 | 0.79 | NPC1 (0.65) | NPC1RAB9AALDH1A1PTPN1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107406424-B | Estrogen receptor modulators and uses thereof | 豪夫迈·罗氏有限公司 | 2020-08-25 | — | — | CN | disclosed |
| EP-3233828-B1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2020-03-04 | — | — | EP | disclosed |
| US-9845291-B2 | Estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2017-12-19 | — | — | US | disclosed |
| EP-3233828-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | F. Hoffmann-La Roche AG (CH) | 2017-10-25 | — | — | EP | disclosed |
| US-20170197915-A9 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2017-07-13 | — | — | US | disclosed |
| US-9540361-B2 | N-substituted azetidine derivatives | MERCK SHARP & DOHME B.V. (NL) | 2017-01-10 | — | — | US | disclosed |
| US-20160304450-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-10-20 | — | — | US | disclosed |
| EP-2655367-B1 | N-SUBSTITUTED AZETIDINE DERIVATIVES | MERCK SHARP & DOHME (NL) | 2016-07-06 | — | — | EP | disclosed |
| WO-2016097071-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2016-06-23 | — | — | WO | disclosed |
| US-20160130262-A1 | N-SUBSTITUTED AZETIDINE DERIVATIVES | MERCK SHARP & DOHME B.V. (NL) | 2016-05-12 | — | — | US | disclosed |
| EP-2655367-A1 | N-SUBSTITUTED AZETIDINE DERIVATIVES | Merck Sharp & Dohme B.V. (NL) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012084711-A1 | N-SUBSTITUTED AZETIDINE DERIVATIVES | MSD OSS B.V. (NL) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012052395-A1 | ISOXAZOLE DERIVATIVES USED AS OESTROGEN MODULATORS | N. V. ORGANON (NL) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197915-A9 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, ESR1, GPER1 | NPC1 2307/4885RAB9A 4035/4885CYP3A4 205/4885 |
| US-20160304450-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, ESR1, GPER1 | NPC1 2307/4885RAB9A 4035/4885CYP3A4 205/4885 |
| US-20160130262-A1 | N-SUBSTITUTED AZETIDINE DERIVATIVES | ESR2, ESR1, GPER1 | NPC1 1783/4885RAB9A 1154/4885CYP3A4 1520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.